Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Weill Cornell experts publish review of genetic medicine

In an article published in the April issue of Nature Reviews Genetics, two experts at the Weill Medical College of Cornell University sum up the achievements, challenges and promise of a burgeoning field: genetic medicine.

3 Apr 2006

Gene therapy treatment for brain tumours and infections

In a study published in the March 15 issue of The Journal of Immunology, researchers at Board of Governors' Gene Therapeutics Research Institute at Cedars-Sinai Medical Center have developed a way to overcome immune privilege in the brain to eradicate potentially deadly brain tumors such as glioblastoma multiforme and other types of brain infections.

27 Mar 2006

Gene therapy tackles hereditary spastic paraplegia

Elena Rugarli and colleagues from the National Neurological Institute in Milan have used gene therapy to save sensory and skeletal muscle nerve fibers from degeneration in mice with hereditary spastic paraplegia (HSP).

15 Dec 2005

Possible therapy that could control blood pressure

A newly developed virus that introduces a blood pressure-lowering gene into cells and enables that gene to maintain blood pressure at healthy levels for four months promises to take gene therapy for the disorder a step closer to reality, said researchers at Baylor College of Medicine in a report released online in the Proceedings of the National Academy of Sciences.

27 Sep 2005

Neurologix announces positive interim results of gene therapy clinical trial for patients with Parkinson's disease

Neurologix has announced positive interim results of its landmark gene therapy clinical trial for patients with Parkinson's disease. Neurologix's 12-patient, dose-escalating Phase I trial is the world's first study to use a viral vector (the non-pathogenic adeno-associated virus, or AAV) for the treatment of an adult neurological disease.

26 Sep 2005

New findings could help scientists design more effective treatments to slow or halt the progression of HIV infection

Random fluctuations in gene expression can influence the fates of cells infected with human immunodeficiency virus (HIV) far more than previously thought, according to new research from Howard Hughes Medical Institute (HHMI) researchers at the University of California, Berkeley.

28 Jul 2005

Gene therapy for arthritis is both feasible and safe

Gene therapy for arthritis and other non-terminal, debilitating conditions and diseases is both feasible and safe, report researchers who conducted the world's first such test on the approach in patients with advanced rheumatoid arthritis.

6 Jun 2005

Scientists develop a way to block the signals responsible for neuropathic pain

Remember how it felt the last time you burned your finger on a hot stove? Imagine what it's like to have that burning pain in your hands or feet all the time and know there's virtually nothing you can do about it.

1 Jun 2005

Interaction between cell and virus provides scientists valuable insights into the development of safe viral vectors for use in oncology

When infected by a virus, a cell uses specific defense mechanisms developed in the course of a long evolution. Thus, it can activate enzymes that disrupt or prevent replication of the viruses within the cell.

1 Jun 2005

Scientists dramatically slow organ transplant rejection

That's the promising implication of an animal study carried out by researchers at the University of Alabama at Birmingham (UAB) and the University of Florida (UF) published in today's (May 2) issue of Proceedings of the National Academy of Sciences.

3 May 2005

India trials investigational vaccine candidate designed to prevent HIV/AIDS

Announcing the trial, Union Minister of Health and Family Welfare Dr. Anbumani Ramadoss, said: "Developing a vaccine to prevent AIDS is one of the most difficult scientific challenges of our time. It is also one of the most urgent health needs. Perseverance is the way forward, and India has a long- term commitment."

7 Feb 2005

Scientists discover breakthrough method to treat neuronal diseases

What do stroke, epilepsy, head or spinal cord trauma, Parkinson’s disease and Alzheimer’s disease patients have in common? They all suffer from neuronal cell death brought about by the absence or malfunction of specific genes.

30 Aug 2004

Proof of principle that it is possible to deliver new genes body-wide to all the muscles of an adult animal

MDA-supported researchers at the University of Washington-Seattle have delivered the gene for the dystrophin protein to all voluntary muscles with a single intravenous injection in mice with Duchenne muscular dystrophy (DMD).

29 Jul 2004

$1.6 million to develop gene therapy strategies for Duchenne muscular dystrophy, a fatal, childhood-onset disease

The Muscular Dystrophy Association has announced it has awarded $1.6 million to Asklepios, a biotechnology company closely allied with the University of North Carolina at Chapel Hill, to develop gene therapy strategies for Duchenne muscular dystrophy (DMD), a fatal, childhood-onset disease.

23 Jul 2004

Gene therapy may provide a treatment for a group of incurable, progressive neurological diseases called polyglutamine-repeat diseases

Researchers from the University of Iowa have have shown for the first time that gene therapy delivered to the brains of living mice can prevent the physical symptoms and neurological damage caused by an inherited neurodegenerative disease that is similar to Huntington's disease (HD).

5 Jul 2004

$3.5 million grant to develop AIDS vaccinations

Researchers at the Vaccine and Gene Therapy Institute (VGTI) and the Oregon National Primate Research Center at Oregon Health & Science University have received a $3.5 million grant from the National Institutes of Health to develop new methods for vaccinating humans against human immunodeficiency virus (HIV), the virus that causes AIDS.

25 May 2004

AMT Obtains Orphan Drug Designation for Its LPL Gene Therapy Product

AMT today announced that its adeno-associated viral vector (AAV) expressing lipoprotein lipase (LPL) product has been designated as an orphan medicinal product for the treatment of LPL deficiency by the European Commission. This decision follows a positive recommendation by the European Agency for the Evaluation of Medicinal Products.

22 Mar 2004